ImmunityBio (NASDAQ:IBRX) Shares Up 13% on Better-Than-Expected Earnings

ImmunityBio, Inc. (NASDAQ:IBRX)’s stock price rose 13% during trading on Monday following a stronger than expected earnings report. The stock traded as high as $11.00 and last traded at $9.83. Approximately 85,988,851 shares traded hands during trading, an increase of 95% from the average daily volume of 44,149,879 shares. The stock had previously closed at $8.70.

The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter.

ImmunityBio News Summary

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Q4 revenue surge — ImmunityBio reported roughly 700% year‑over‑year revenue growth driven by ANKTIVA commercial sales and cited expanded ANKTIVA approvals (including lung cancer) and global commercial partnerships in ~33 countries — a clear revenue catalyst. ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships
• Positive Sentiment: Earnings beat — Q4 loss per share was $0.06 vs. the consensus loss of $0.08 (and improved from a $0.15 loss a year ago); revenue of ~$38.28M topped estimates, signaling improving economics as ANKTIVA sales ramp. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Analyst support — D. Boral Capital reaffirmed a “buy” rating and set a $23 price target, indicating strong bullish sentiment from at least one sell‑side shop and potentially supporting further upside if execution continues. Benzinga coverage of analyst rating
• Neutral Sentiment: Investor visibility event — Founder Dr. Patrick Soon‑Shiong will speak at the Milken Institute & Richard Nixon Foundation “Cancer 2035” summit; this raises profile and could help outreach but has no immediate operational impact. ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken Institute and Richard Nixon Foundation “Cancer 2035” Summit
• Neutral Sentiment: Management commentary — Chairman teased a 3‑year expansion plan for ANKTIVA and hinted at potential breakthroughs; bullish messaging can support sentiment but is forward‑looking and execution‑dependent. IBRX stock to open week on a high? Chairman teases Anktiva’s 3-year expansion plans
• Negative Sentiment: Profitability risk remains — despite the beat, ImmunityBio is still operating at a loss and consensus estimates show negative EPS for the year (the company’s valuation depends heavily on ANKTIVA scaling and further approvals). ImmunityBio Q4 press release / financials

Analysts Set New Price Targets

A number of research firms recently commented on IBRX. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of ImmunityBio in a research report on Monday. D. Boral Capital restated a “buy” rating and set a $23.00 target price on shares of ImmunityBio in a report on Monday. The Goldman Sachs Group restated a “buy” rating on shares of ImmunityBio in a research note on Monday. BTIG Research upped their price target on shares of ImmunityBio from $6.00 to $9.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Finally, Jefferies Financial Group increased their price objective on shares of ImmunityBio from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, ImmunityBio presently has an average rating of “Moderate Buy” and an average target price of $12.60.

Insider Transactions at ImmunityBio

In related news, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $7.51, for a total value of $187,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Barry J. Simon sold 151,967 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the transaction, the director owned 3,091,604 shares in the company, valued at approximately $22,259,548.80. The trade was a 4.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 226,967 shares of company stock valued at $1,531,912. Corporate insiders own 69.48% of the company’s stock.

Institutional Trading of ImmunityBio

A number of institutional investors have recently bought and sold shares of the business. Armistice Capital LLC acquired a new position in shares of ImmunityBio in the 2nd quarter valued at $20,497,000. Heights Capital Management Inc. bought a new stake in ImmunityBio in the third quarter valued at about $16,152,000. Vanguard Group Inc. increased its holdings in ImmunityBio by 26.8% in the third quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company’s stock valued at $68,032,000 after purchasing an additional 5,837,898 shares during the last quarter. State Street Corp lifted its stake in ImmunityBio by 45.4% in the fourth quarter. State Street Corp now owns 16,455,703 shares of the company’s stock valued at $32,582,000 after buying an additional 5,139,890 shares during the period. Finally, Goldman Sachs Group Inc. boosted its holdings in ImmunityBio by 439.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company’s stock worth $12,182,000 after buying an additional 5,012,001 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Stock Performance

The company has a market capitalization of $9.68 billion, a price-to-earnings ratio of -23.98 and a beta of 0.14. The company has a 50-day moving average price of $4.63 and a 200-day moving average price of $3.17.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.